Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 22, 2019

SELL
$26.26 - $34.86 $184,213 - $244,542
-7,015 Closed
0 $0
Q2 2019

Jul 23, 2019

BUY
$17.43 - $28.82 $122,271 - $202,172
7,015 New
7,015 $186,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.23B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Convergence Investment Partners, LLC Portfolio

Follow Convergence Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Convergence Investment Partners, LLC with notifications on news.